Neprilysin (Neutral Endopeptidase 24.11 or Atriopeptidase or
Common Acute Lymphocytic Leukemia Antigen or Skin Fibroblast Elastase or
Enkephalinase or CD10 or MME or EC 3.4.24.11) - Pipeline Review, H2 2016’,
provides in depth analysis on Neprilysin (Neutral Endopeptidase 24.11 or
Atriopeptidase or Common Acute Lymphocytic Leukemia Antigen or Skin Fibroblast
Elastase or Enkephalinase or CD10 or MME or EC 3.4.24.11) targeted pipeline
therapeutics.
Get Sample Report @ https://www.wiseguyreports.com/sample-request/711806-neprilysin-neutral-endopeptidase-24-review-h2-2016
The report provides comprehensive information on the
Neprilysin (Neutral Endopeptidase 24.11 or Atriopeptidase or Common Acute
Lymphocytic Leukemia Antigen or Skin Fibroblast Elastase or Enkephalinase or
CD10 or MME or EC 3.4.24.11) , targeted therapeutics, complete with analysis by
indications, stage of development, mechanism of action (MoA), route of
administration (RoA) and molecule type. The report also covers the descriptive
pharmacological action of the therapeutics, its complete research and development
history and latest news and press releases. Additionally, the report provides
an overview of key players involved in Neprilysin (Neutral Endopeptidase 24.11
or Atriopeptidase or Common Acute Lymphocytic Leukemia Antigen or Skin
Fibroblast Elastase or Enkephalinase or CD10 or MME or EC 3.4.24.11) targeted
therapeutics development and features dormant and discontinued projects.
Report features investigational drugs from across globe
covering over 20 therapy areas and nearly 3,000 indications. Drug profiles
featured in the report undergoes periodic review following a stringent set of
processes to ensure that all the profiles are updated with the latest set of
information. Additionally, various dynamic tracking processes ensure that the
most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging
players in the market and their portfolios, enhances decision making
capabilities and helps to create effective counter strategies to gain
competitive advantage.
Scope
- The report provides a snapshot of the global therapeutic
landscape for Neprilysin (Neutral Endopeptidase 24.11 or Atriopeptidase or
Common Acute Lymphocytic Leukemia Antigen or Skin Fibroblast Elastase or
Enkephalinase or CD10 or MME or EC 3.4.24.11)
- The report reviews Neprilysin (Neutral Endopeptidase 24.11
or Atriopeptidase or Common Acute Lymphocytic Leukemia Antigen or Skin
Fibroblast Elastase or Enkephalinase or CD10 or MME or EC 3.4.24.11) targeted
therapeutics under development by companies and universities/research
institutes based on information derived from company and industry-specific
sources
- The report covers pipeline products based on various
stages of development ranging from pre-registration till discovery and undisclosed
stages
- The report features descriptive drug profiles for the
pipeline products which includes, product description, descriptive MoA, R&D
brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Neprilysin
(Neutral Endopeptidase 24.11 or Atriopeptidase or Common Acute Lymphocytic
Leukemia Antigen or Skin Fibroblast Elastase or Enkephalinase or CD10 or MME or
EC 3.4.24.11) targeted therapeutics and enlists all their major and minor projects
- The report assesses Neprilysin (Neutral Endopeptidase
24.11 or Atriopeptidase or Common Acute Lymphocytic Leukemia Antigen or Skin
Fibroblast Elastase or Enkephalinase or CD10 or MME or EC 3.4.24.11) targeted
therapeutics based on mechanism of action (MoA), route of administration (RoA)
and molecule type
- The report summarizes all the dormant and discontinued
pipeline projects
- The report reviews latest news and deals related to
Neprilysin (Neutral Endopeptidase 24.11 or Atriopeptidase or Common Acute
Lymphocytic Leukemia Antigen or Skin Fibroblast Elastase or Enkephalinase or
CD10 or MME or EC 3.4.24.11) targeted therapeutics
Reasons to buy
- Gain strategically significant competitor information,
analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product
portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and
indications for Neprilysin (Neutral Endopeptidase 24.11 or Atriopeptidase or
Common Acute Lymphocytic Leukemia Antigen or Skin Fibroblast Elastase or
Enkephalinase or CD10 or MME or EC 3.4.24.11)
- Identify the use of drugs for target identification and
drug repurposing
- Identify potential new clients or partners in the target
demographic
- Develop strategic initiatives by understanding the focus
areas of leading companies
- Plan mergers and acquisitions effectively by identifying
key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by
understanding Neprilysin (Neutral Endopeptidase 24.11 or Atriopeptidase or
Common Acute Lymphocytic Leukemia Antigen or Skin Fibroblast Elastase or
Enkephalinase or CD10 or MME or EC 3.4.24.11) development landscape
- Develop and design in-licensing and out-licensing
strategies by identifying prospective partners with the most attractive
projects to enhance and expand business potential and scope
Table of
Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Neprilysin (Neutral Endopeptidase 24.11 or Atriopeptidase or
Common Acute Lymphocytic Leukemia Antigen or Skin Fibroblast Elastase or
Enkephalinase or CD10 or MME or EC 3.4.24.11) Overview 7
Therapeutics Development 8
Neprilysin (Neutral Endopeptidase 24.11 or Atriopeptidase or
Common Acute Lymphocytic Leukemia Antigen or Skin Fibroblast Elastase or
Enkephalinase or CD10 or MME or EC 3.4.24.11) - Products under Development by
Stage of Development 8
Neprilysin (Neutral Endopeptidase 24.11 or Atriopeptidase or
Common Acute Lymphocytic Leukemia Antigen or Skin Fibroblast Elastase or
Enkephalinase or CD10 or MME or EC 3.4.24.11) - Products under Development by
Therapy Area 9
Neprilysin (Neutral Endopeptidase 24.11 or Atriopeptidase or
Common Acute Lymphocytic Leukemia Antigen or Skin Fibroblast Elastase or
Enkephalinase or CD10 or MME or EC 3.4.24.11) - Products under Development by
Indication 10
Neprilysin (Neutral Endopeptidase 24.11 or Atriopeptidase or
Common Acute Lymphocytic Leukemia Antigen or Skin Fibroblast Elastase or
Enkephalinase or CD10 or MME or EC 3.4.24.11) - Pipeline Products Glance 11
Late Stage Products 11
Early Stage Products 12
Neprilysin (Neutral Endopeptidase 24.11 or Atriopeptidase or
Common Acute Lymphocytic Leukemia Antigen or Skin Fibroblast Elastase or
Enkephalinase or CD10 or MME or EC 3.4.24.11) - Products under Development by
Companies 13
Neprilysin (Neutral Endopeptidase 24.11 or Atriopeptidase or
Common Acute Lymphocytic Leukemia Antigen or Skin Fibroblast Elastase or
Enkephalinase or CD10 or MME or EC 3.4.24.11) - Therapeutics Assessment 15
Assessment by Monotherapy/Combination Products 15
Assessment by Mechanism of Action 16
Assessment by Route of Administration 17
Assessment by Molecule Type 19
Neprilysin (Neutral Endopeptidase 24.11 or Atriopeptidase or
Common Acute Lymphocytic Leukemia Antigen or Skin Fibroblast Elastase or
Enkephalinase or CD10 or MME or EC 3.4.24.11) - Companies Involved in
Therapeutics Development 21
Bioprojet SCR 21
Novartis AG 22
Pharmaleads SA 23
Theravance Biopharma, Inc. 24
Neprilysin (Neutral Endopeptidase 24.11 or Atriopeptidase or
Common Acute Lymphocytic Leukemia Antigen or Skin Fibroblast Elastase or
Enkephalinase or CD10 or MME or EC 3.4.24.11) - Drug Profiles 25
(sacubitril + valsartan) - Drug Profile 25
Product Description 25
Mechanism Of Action 25
R&D Progress 25
dexecadotril - Drug Profile 30
Product Description 30
Mechanism Of Action 30
R&D Progress 30
PL-265 - Drug Profile 31
Product Description 31
Mechanism Of Action 31
R&D Progress 31
PL-37 - Drug Profile 32
Product Description 32
Mechanism Of Action 32
R&D Progress 32
Access Report @ https://www.wiseguyreports.com/reports/711806-neprilysin-neutral-endopeptidase-24-review-h2-2016
Contact Info:
NORAH TRENT
Partner Relations
& Marketing Manager
Ph:
+1-646-845-9349 (US)
Ph: +44 208 133 9349 (UK)
Get
in touch:
LinkedIn:
www.linkedin.com/company/4828928
Twitter:
https://twitter.com/WiseGuyReports
Facebook: https://www.facebook.com/Wiseguyreports-1009007869213183/?fref=ts
No comments:
Post a Comment